Clinical Insights in Myelofibrosis: Addressing Unmet Needs & Advancing Outcomes - Episode 2

Tackling Complex Clinical Scenarios: MF Patients With Thrombocytopenia and Anemia

,

Panelists discuss the latest data on pacritinib’s effects on anemia and bicytopenia, and share their treatment approaches for patients with myelofibrosis who present with both thrombocytopenia and anemia.

EP. 1: Clinical Perspectives: Firstline Treatment Landscape in Higher-Risk MF
Now Viewing
EP. 2: Tackling Complex Clinical Scenarios: MF Patients With Thrombocytopenia and Anemia
EP. 3: Challenges With Defining “Ruxolitinib Failure” or Suboptimal Response to Ruxolitinib in MF
EP. 4: Clinical Insights on Managing Ruxolitinib Cytopenias: Patient-Focused Approach
  1. Dr Kuykendall: Please briefly share the data and your impressions on pacritinib’s anemia and bicytopenia data.
  2. Dr Kuykendall to Dr Konala: What is your general treatment approach for patients who present with both thrombocytopenia and anemia? 

Related Content:

Clinical Insights in Myelofibrosis: Addressing Unmet Needs & Advancing Outcomes
Clinical Insights on Managing Ruxolitinib Cytopenias: Patient-Focused Approach
Challenges With Defining “Ruxolitinib Failure” or Suboptimal Response to Ruxolitinib in MF
Clinical Perspectives: Firstline Treatment Landscape in Higher-Risk MF